Amicus Therapeutics (FOLD), a global biotechnology company focused on developing and commercializing novel medicines for rare diseases, reported a strong start to the year, prompting it to raise its product guidance recently.
The company markets Galafold for Fabry disease and Pombiliti + Opfolda, a two-component therapy, to treat late-onset Pompe disease.
Fabry and Pompe diseases are rare inherited disorders characterized by enzyme deficiencies. Fabry disease results from fat buildup, affecting multiple organs and blood vessels, while Pompe disease involves glycogen accumulation due to lack of a specific enzyme, causing progressive muscle weakness, particularly in late-onset cases.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.